{"id":40244,"date":"2025-08-27T15:10:27","date_gmt":"2025-08-27T07:10:27","guid":{"rendered":"https:\/\/flcube.com\/?p=40244"},"modified":"2025-08-27T15:10:28","modified_gmt":"2025-08-27T07:10:28","slug":"fosun-pharma-grants-sitala-global-license-for-fxs6837-up-to-190-m-milestones","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40244","title":{"rendered":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones"},"content":{"rendered":"\n<p>Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) today announced a <strong>License Agreement<\/strong> with UK\u2011based biotechnology company <strong>Sitala<\/strong>. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor <strong>FXS6837<\/strong> and any products containing this active ingredient <strong>globally, excluding China<\/strong> (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.<\/p>\n\n\n\n<p><strong>Deal Snapshot<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensed Product<\/strong><\/td><td>FXS6837 \u2013 proprietary immune\u2011regulation inhibitor<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Worldwide, <em>excluding<\/em> China, HK, Macau, Taiwan<\/td><\/tr><tr><td><strong>Current Clinical Status<\/strong><\/td><td>Phase\u202f2 trials in China<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f25\u202fM (non\u2011refundable)<\/td><\/tr><tr><td><strong>Total Development &amp; Commercialisation Milestones<\/strong><\/td><td>Up to USD\u202f190\u202fM<\/td><\/tr><tr><td><strong>Sales Milestone Payments<\/strong><\/td><td>Up to USD\u202f480\u202fM (based on annual net sales)<\/td><\/tr><tr><td><strong>Royalty Structure<\/strong><\/td><td>Double\u2011digit % of annual net sales (exact % TBD)<\/td><\/tr><tr><td><strong>Share\u2011Acquisition Option<\/strong><\/td><td>Fosun (or affiliate) may acquire up to USD\u202f5\u202fM worth of Sitala shares at zero cost; resulting stake not to exceed 10\u202f% (fully diluted)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Financial Highlights<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Cash Flow<\/strong> \u2013 Immediate USD\u202f25\u202fM injection into Fosun\u2019s balance sheet.<\/li>\n\n\n\n<li><strong>Milestone Upside<\/strong> \u2013 Potential cumulative cash inflows approaching USD\u202f670\u202fM if all milestones are hit.<\/li>\n\n\n\n<li><strong>Royalty Revenue<\/strong> \u2013 Long\u2011term, scalable income tied to product performance.<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Rationale<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Global Reach<\/strong> \u2013 Sitala\u2019s established R&amp;D and manufacturing platforms enable rapid development outside China, where Fosun currently has no presence.<\/li>\n\n\n\n<li><strong>Portfolio Diversification<\/strong> \u2013 FXS6837 adds a novel immune\u2011modulatory agent to Sitala\u2019s pipeline, strengthening its position in the competitive biopharma landscape.<\/li>\n\n\n\n<li><strong>Shared Risk &amp; Reward<\/strong> \u2013 Milestone and royalty structures align incentives, mitigating upfront risk for Fosun while providing upside for both parties.<\/li>\n<\/ul>\n\n\n\n<p><strong>Next Steps<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Regulatory Filing<\/strong> \u2013 Sitala will prepare and submit IND\/CTAs for global markets, leveraging Fosun\u2019s Phase\u202f2 data.<\/li>\n\n\n\n<li><strong>Manufacturing Scale\u2011Up<\/strong> \u2013 Establish production sites compliant with GMP for FXS6837.<\/li>\n\n\n\n<li><strong>Commercialisation Plan<\/strong> \u2013 Joint market entry strategy targeting immune\u2011regulation indications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600196_20250827_EA3Y.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20250827_EA3Y.\"><\/object><a id=\"wp-block-file--media-b4341f51-7b50-4ae1-bf1d-54765aff23cc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600196_20250827_EA3Y.pdf\">600196_20250827_EA3Y<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/600196_20250827_EA3Y.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b4341f51-7b50-4ae1-bf1d-54765aff23cc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,159,893,892,4315],"class_list":["post-40244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196","tag-sitala"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement with UK\u2011based biotechnology company Sitala. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor FXS6837 and any products containing this active ingredient globally, excluding China (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40244\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement with UK\u2011based biotechnology company Sitala. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor FXS6837 and any products containing this active ingredient globally, excluding China (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40244\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T07:10:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-27T07:10:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones\",\"datePublished\":\"2025-08-27T07:10:27+00:00\",\"dateModified\":\"2025-08-27T07:10:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2710.webp\",\"keywords\":[\"Biotech\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\",\"Sitala\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40244#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40244\",\"name\":\"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2710.webp\",\"datePublished\":\"2025-08-27T07:10:27+00:00\",\"dateModified\":\"2025-08-27T07:10:28+00:00\",\"description\":\"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement with UK\u2011based biotechnology company Sitala. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor FXS6837 and any products containing this active ingredient globally, excluding China (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40244\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2710.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2710.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40244#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement with UK\u2011based biotechnology company Sitala. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor FXS6837 and any products containing this active ingredient globally, excluding China (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40244","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones","og_description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement with UK\u2011based biotechnology company Sitala. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor FXS6837 and any products containing this active ingredient globally, excluding China (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.","og_url":"https:\/\/flcube.com\/?p=40244","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-27T07:10:27+00:00","article_modified_time":"2025-08-27T07:10:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40244#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40244"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones","datePublished":"2025-08-27T07:10:27+00:00","dateModified":"2025-08-27T07:10:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40244"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp","keywords":["Biotech","Fosun Pharmaceutical","HKG: 2196","SHA: 600196","Sitala"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40244#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40244","url":"https:\/\/flcube.com\/?p=40244","name":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40244#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp","datePublished":"2025-08-27T07:10:27+00:00","dateModified":"2025-08-27T07:10:28+00:00","description":"Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement with UK\u2011based biotechnology company Sitala. The deal gives Sitala exclusive rights to develop, manufacture and commercialise the small\u2011molecule inhibitor FXS6837 and any products containing this active ingredient globally, excluding China (including Hong Kong, Macau and Taiwan) for the diagnosis and treatment of human and animal diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40244#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40244"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40244#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp","width":1080,"height":608,"caption":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40244#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Grants Sitala Global License for FXS6837 \u2013 Up to $190\u202fM Milestones"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2710.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40244"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40244\/revisions"}],"predecessor-version":[{"id":40248,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40244\/revisions\/40248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40247"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}